CD80 antibody (Extracellular Domain)
-
- Target See all CD80 Antibodies
- CD80
-
Binding Specificity
- Extracellular Domain
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This CD80 antibody is un-conjugated
-
Application
- Flow Cytometry (FACS), Immunoprecipitation (IP)
- Specificity
- The antibody MEM-233 reacts with an extracellular epitope of CD80 (B7-1), a 60 kDa single chain type I glycoprotein of immunoglobulin supergene family, expressed on professional antigen-presenting cells, such as dendritic cells, macrophages or activated B lymphocytes.
- Cross-Reactivity (Details)
- Human
- Purification
- Purified by protein-A affinity chromatography.
- Purity
- > 95 % (by SDS-PAGE)
- Immunogen
- Extracellular domain of human CD80 fused to human IgG1(Fc)
- Clone
- MEM-233
- Isotype
- IgG1
- Top Product
- Discover our top product CD80 Primary Antibody
-
-
- Application Notes
- Flow cytometry: Recommended dilution: 1-4 μg/mL.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
- Do not freeze.
- Storage
- 4 °C
- Storage Comment
- Store at 2-8°C. Do not freeze.
-
-
Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype." in: Journal of biomedicine & biotechnology, Vol. 2012, pp. 172420, (2012) (PubMed).
: "Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses." in: BMC immunology, Vol. 12, pp. 2, (2011) (PubMed).
: "LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 12, pp. 8128-36, (2007) (PubMed).
: "A novel human B cell subpopulation representing the initial germinal center population to express AID." in: Blood, Vol. 109, Issue 6, pp. 2545-52, (2007) (PubMed).
: "Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment." in: Haematologica, Vol. 91, Issue 3, pp. 364-8, (2006) (PubMed).
: "Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination." in: Molecular therapy : the journal of the American Society of Gene Therapy, Vol. 11, Issue 5, pp. 790-800, (2005) (PubMed).
: "The immunomodulatory role of human conjunctival epithelial cells." in: Investigative ophthalmology & visual science, Vol. 44, Issue 9, pp. 3906-10, (2003) (PubMed).
: "
-
Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype." in: Journal of biomedicine & biotechnology, Vol. 2012, pp. 172420, (2012) (PubMed).
-
- Target
- CD80
- Alternative Name
- CD80 (CD80 Products)
- Synonyms
- B7 antibody, B7-1 antibody, B7.1 antibody, BB1 antibody, CD28LG antibody, CD28LG1 antibody, LAB7 antibody, B71 antibody, Cd28l antibody, Ly-53 antibody, Ly53 antibody, MIC17 antibody, TSA1 antibody, CD80 molecule antibody, Cd80 molecule antibody, CD80 antigen antibody, CD80 antibody, Cd80 antibody
- Background
- CD80 Molecule,CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CTLA-4 (CD152). The both B7 Molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, the both molecules can also substitute for each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet, there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.,B7-1, BB1
- Gene ID
- 941
- UniProt
- P33681
- Pathways
- TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
-